Veltassa, a sodium-free potassium binder treatment for hyperkalaemia, has been approved for marketing by the European Commission (EC) with the first launches planned for the end of this year or early next year. more

21 Jul 2017 11:32 News

Veltassa (patiromer), developed by Relypsa, has received a recommendation for marketing approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of hyperkalaemia. more

19 May 2017 12:07 News